Jump to the top of the page

The Eimen Kaminski Group

William Blair Private Wealth Management

The Eimen-Kaminski Team

About William Blair

William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*

  • 1935

    Year William Blair was founded

  • 1,900+

    Employees worldwide

  • 149 billion+

    Client assets

  • 89 Years

    Independent and employee-owned

  • 20+

    Offices worldwide

  • ~650

    Companies under coverage

As of September 30, 2024
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.

More about William Blair affiliated entities

Thought Leadership

  • The 2024 Tax Reference Guide is Now Available

    William Blair's tax reference guide for income earned in 2024 and tax returns filed in 2025 is now available.

    Read more
  • Asset Allocation: Your Biggest Investment Decision

    Building a portfolio involves countless decisions. But none is more important than how you allocate your wealth across asset classes. This white paper describes the process of developing a customized asset-allocation strategy, achieving meaningful diversification across and within asset classes, and monitoring allocations and reviewing portfolios.

    Read more
  • 529 Plan Account Rollovers to Roth IRAs

    529 plan account owners or beneficiaries can roll over 529 plans into a beneficiary-owned Roth IRA tax-free and penalty-free as of January 1, 2024, subject to certain limitations.

    Read more

Our Latest News

  • Elevation Oncology, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Elevation Oncology, Inc. (ELEV $0.56), a clinical-stage biotechnology company advancing a Phase I antibody-drug conjugate (ADC) against claudin 18.2, initially targeting gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma with pancreatic cancer as an expansion opportunity.

    Read more
  • Denali Therapeutics Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Denali Therapeutics Inc. (DNLI $20.38), a clinical-stage biotechnology company developing treatments for CNS and other indications by leveraging its unique blood–brain barrier penetrating technology platform.

    Read more
  • APi Group Corporation: Initiation of Research Coverage

    William Blair initiated research coverage of APi Group Corporation (APG $37.65), the global leader in life safety services, with a total addressable market that is estimated to exceed $150 billion.

    Read more

Ready to start a conversation? Contact us today.

This content is for informational and educational purposes only and not intended as investment advice or a recommendation to buy or sell any security. Investment advice and recommendations can be provided only after careful consideration of an investor's objectives, guidelines, and restrictions.

Copyright © 2025 William Blair & Company, L.L.C. | Privacy Terms

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures